Key Highlights
- Eli Lilly Launches Strategic Technology & Innovation Center in Hyderabad Focused on AI, Automation, and Cloud Technologies
The facility aims to accelerate drug discovery and delivery, leveraging advanced computing to enhance operational efficiency and improve patient outcomes worldwide. - Initial 100 Professionals Onboard, Scaling to 1,500 in Coming Years Amid Telangana’s Growing Healthcare Innovation Ecosystem
This strategic expansion taps into Hyderabad’s skilled digital and scientific talent pool, reinforcing India’s role as a global hub for life sciences and digital transformation. - Robust Government Support Signals Public-Private Collaboration Driving US Pharma’s Global Digital Leadership
State leaders highlight Hyderabad’s evolution as a digital innovation hotspot, while Eli Lilly integrates AI and cloud engineering to speed next-gen therapeutic development.
Strategic Digital Operations Hub Anchors Eli Lilly’s Global Innovation Ambitions
Eli Lilly’s Hyderabad facility located in Gachibowli spans 220,000 sq ft across four floors and is designed to serve as a central hub for the company’s digital and technology capabilities worldwide. As part of its commitment to digital transformation, the site will focus heavily on artificial intelligence, automation, cloud computing, and software product engineering, fuelling accelerated development timelines and data-driven R&D.
Scaling Talent and AI Excellence in India’s Scientific Ecosystem
Since officially opening in August 2025, the Hyderabad site has onboarded 100 technology professionals specializing in AI, data science, and software engineering. The workforce is expected to expand to 1,500 in the next few years, enhancing the company’s ability to integrate AI-enabled innovation into all phases of drug discovery, clinical trials, manufacturing, and commercialization.
Government and Industry Leaders Endorse Hyderabad as a Global Healthcare Digital Hub
Telangana’s Chief Minister A. Revanth Reddy and other government officials praised the facility launch as a validation of Hyderabad’s rapid emergence as a life sciences and digital innovation epicenter. Their support underscores the strategic importance of public-private partnerships in fostering advanced healthcare technologies and attracting global pharma investment.
AI and Cloud-Driven Innovation to Accelerate Next-Generation Medicine Delivery
Eli Lilly plans to leverage this tech and digital center to drive cutting-edge innovation in drug discovery and development pipelines. The integration of AI with traditional pharmaceutical expertise aims to shorten development cycles, reduce costs, and enhance precision medicine approaches, ultimately delivering improved health outcomes on a global scale.
By